Elanix Biotechnologies AG

  • WKN: A0WMJQ
  • ISIN: DE000A0WMJQ4
  • Land: Deutschland

Nachricht vom 14.02.2019 | 00:47

Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

Elanix Biotechnologies AG / Key word(s): Legal Matter/Miscellaneous
Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

14-Feb-2019 / 00:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

Berlin, February 14, 2019 - Previous ad hoc announcement (February 11, 2019) of Elanix Biotechnologies AG ("Company") mentioned mismanagement during the tenure of former CEO Tomas J. Svoboda. After further detailed examination of the situation of the company by current management and legal team, evidence was gathered to constitute criminal charges to be filed against former CEO Tomas J. Svoboda. The full charges will be filed without delay against Mr. Svoboda on the suspicion of several crimes, amongst others breach of trust and balance sheet manipulation. It is expected that the misconduct will lead or already led to considerable extraordinary expenses. Further and detailed information regarding the extent of the damage done to the company will be independently confirmed.

Lee Ann Laurent-Applegate
CEO

Contacts

Elanix Biotechnologies AG
Lee Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
investor.relations@elanix-bt.com

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


14-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.

GBC-Fokusbox

Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

E.ON SE: E.ON zeigt Stärke und Zuverlässigkeit in der Krise

28. Mai 2020, 12:00

Aktuelle Research-Studie

Aroundtown SA

Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): BUY

28. Mai 2020